Insider · CIK 0001556064
Garry E Menzel
Files at STOK (Stoke Therapeutics, Inc.), BDTX (Black Diamond Therapeutics, Inc.). First filing -, latest -.
In brief
Garry E Menzel files SEC Form 4 as director at STOK (Stoke Therapeutics, Inc.), and also at BDTX (Black Diamond Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Garry E Menzel has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | BDTX Black Diamond Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jun 29, 2026 |
| Jun 12, 2025 | BDTX Black Diamond Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +30,550 | $0.00 | $0 | 30,550 | Jun 12, 2025 |
| Jun 3, 2025 | STOK Stoke Therapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +29,747 | $0.00 | $0 | 29,747 | Jun 4, 2025 |
Questions about Garry E Menzel
Answered from the filings on this page, as of the latest one.
Is Garry E Menzel buying or selling?
Garry E Menzel has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Garry E Menzel's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Garry E Menzel has 0.
Where does Garry E Menzel file Form 4?
Garry E Menzel has filed Form 4 at STOK (Stoke Therapeutics, Inc.); BDTX (Black Diamond Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.